Skip to main content

Table 3 Frequencies of the analyzed single-nucleotide polymorphism (SNPs), before treatment (D0) and in recurrent infections after treatment with artemether-lumefantrine (R0)

From: Effectiveness of artemether-lumefantrine provided by community health workers in under-five children with uncomplicated malaria in rural Tanzania: an open label prospective study

   Frequencies, (pure+mix)/total*, % (95%CI)
   pfmdr1 N86 pfcrt K76
D0      
  All patients (115+56)/234 73.1 (67.4-78.8)a (152+41)/232 83.2 (78.3-88.0)
  Patients with recrudescence during follow-up (5+8)/13 100.0 (100.0-100.0) (7+5)/13 92.3 (75.6-100.0)
  Patients with reinfection during follow-up (53+33)/115 74.8 (66.7-82.8)b (71+23)/113 83.2 (76.2-90.2)
R0      
  All patients (99+30)/138 93.5 (89.3-97.7)a (92+15)/126 84.9 (78.6-91.3)
  Patients with recrudescence (12+2)/14 100.0 (100.0-100.0) (9+2)/13 84.6 (61.9-100.0)
  Patients with new infection (79+25)/112 92.9 (88.0-97.7)b (74+13)/104 83.7 (76.4-90.9)
  1. * denotes the total no of successful analyses; CI, confidence interval
  2. * denotes the total no of successful analyses; CI, confidence interval
  3. aStatistically significant increase between baseline and all recurrent infections, P < 0.0001
  4. bStatistically significant increase between baseline and only reinfections, P = 0002